A systemic review found that metformin use reduced the risk of prostate cancer among men with diabetes [13] perhaps by regulating adenosine monophosphate-activated protein kinase (AMPK) pathways [10] and mammalian target of rapamycin (mTOR) [12]. The gene discussed is MTOR; the disease is prostate cancer.